## Jean-Francois Bergmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/890982/publications.pdf

Version: 2024-02-01

126 papers 6,445 citations

147566 31 h-index 69108

g-index

144 all docs

144 docs citations

times ranked

144

6288 citing authors

#	Article	IF	CITATIONS
1	Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, The, 2008, 371, 387-394.	6.3	1,258
2	Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients. Chest, 2007, 132, 936-945.	0.4	446
3	Intravitreal triamcinolone acetonide for diabetic diffuse macular edema11The authors have no proprietary interest in this study. 22Dr Audren, co–first author, contributed equally to the work Ophthalmology, 2004, 111, 218-224.	2.5	408
4	Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. Chest, 2011, 140, 706-714.	0.4	401
5	Factors at Admission Associated With Bleeding Risk in Medical Patients. Chest, 2011, 139, 69-79.	0.4	347
6	Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation. Archives of Internal Medicine, 2006, 166, 719.	4.3	265
7	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis, 2005, 94, 750-9.	1.8	173
8	Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. The Cochrane Library, 2015, , CD005049.	1.5	168
9	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis, 2005, , .	1.8	162
10	Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients. New England Journal of Medicine, 2011, 365, 2463-2472.	13.9	145
11	Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunology and Medical Microbiology, 2008, 53, 107-113.	2.7	144
12	Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function. Thrombosis and Haemostasis, 2007, 97, 581-586.	1.8	113
13	Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmologica, 2006, 84, 624-630.	0.4	94
14	Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey). Annals of Surgery, 2010, 251, 330-338.	2.1	93
15	Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. Thrombosis and Haemostasis, 2010, 103, 736-748.	1.8	86
16	Pharmacokinetic–Pharmacodynamic Modeling of the Effect of Triamcinolone Acetonide on Central Macular Thickness in Patients with Diabetic Macular Edema. , 2004, 45, 3435.		83
17	Intravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema: Phase 2 Trial Comparing 4 mg vs 2 mg. American Journal of Ophthalmology, 2006, 142, 794-799.e2.	1.7	80
18	Skin lightening and its complications among AfricanÂpeople living in Paris. Journal of the American Academy of Dermatology, 2006, 55, 873-878.	0.6	79

#	Article	IF	CITATIONS
19	Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation., 2007,, CD005049.		70
20	Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects. Molecular Pharmaceutics, 2016, 13, 2631-2640.	2.3	69
21	Heparin prophylaxis in bedridden patients. Lancet, The, 1996, 348, 205-206.	<b>6.</b> 3	65
22	Etiologies and Management of Aseptic Meningitis in Patients Admitted to an Internal Medicine Department. Medicine (United States), 2016, 95, e2372.	0.4	61
23	Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. , 2012, , CD005049.		59
24	Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. British Journal of Clinical Pharmacology, 2009, 67, 511-519.	1.1	57
25	Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005) Tj ETQq $1\ 1\ 0.7$	/84314 rgE 1.0	BT/Overloc <mark>k</mark>
26	Effect of a Roux-en-Y Gastric Bypass on the Pharmacokinetics of Oral Morphine Using a Population Approach. Clinical Pharmacokinetics, 2014, 53, 919-930.	1.6	51
27	Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica, 2006, 91, 1621-7.	1.7	51
28	Elderly Medical Patients Treated with Prophylactic Dosages of Enoxaparin. Drugs and Aging, 2007, 24, 63-71.	1.3	47
29	Sensory Impairment in Obese Patients? Sensitivity and Pain Detection Thresholds for Electrical Stimulation After Surgery-induced Weight Loss, and Comparison With a Nonobese Population. Clinical Journal of Pain, 2013, 29, 43-49.	0.8	46
30	Predictive Factors of Chronic Post-Surgical Pain at 6 Months Following Knee Replacement: Influence of Postoperative Pain Trajectory and Genetics. Pain Physician, 2016, 19, E729-41.	0.3	43
31	Hepatitis B Virusâ€Hepatitis D Virus motherâ€toâ€child coâ€transmission: A retrospective study in a developed country. Liver International, 2018, 38, 611-618.	1.9	37
32	Risks versus Benefits of NSAIDs Including Aspirin in Myocarditis. Drug Safety, 2003, 26, 975-981.	1.4	33
33	Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. Intensive Care Medicine, 2009, 35, 417-429.	3.9	33
34	A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. Thrombosis Research, 2012, 129, 693-699.	0.8	33
35	Thromboprophylaxis in Medical Patients: Focus on France. Seminars in Thrombosis and Hemostasis, 2002, 28, 051-056.	1.5	31
36	Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. European Journal of Clinical Pharmacology, 2011, 67, 309-314.	0.8	31

#	Article	lF	CITATIONS
37	Hepatitis E Virus infection in HIV-infected patients with elevated serum transaminases levels. Virology Journal, 2011, 8, 171.	1.4	31
38	D-dimer can predict survival in patients with chronic atrial fibrillation. Blood Coagulation and Fibrinolysis, 2004, 15, 413-417.	0.5	30
39	Improving HIV Infection Management Using Antiretroviral Plasma Drug Levels Monitoring: A Clinicians Point of View. Current HIV Research, 2004, 2, 309-321.	0.2	29
40	Circadian Fluctuations of Macular Edema in Patients with Morning Vision Blurring: Correlation with Arterial Pressure and Effect of Light Deprivation., 2005, 46, 4707.		28
41	Pain management and pain characteristics in obese and normal weight patients before joint replacement. Journal of Evaluation in Clinical Practice, 2014, 20, 611-616.	0.9	27
42	Management of Xerostomia in Older Patients. Drugs and Aging, 2007, 24, 957-965.	1.3	26
43	The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2010, 21, 946-958.	0.8	25
44	Self-medication: from European regulatory directives to therapeutic strategy. Fundamental and Clinical Pharmacology, 2003, 17, 275-280.	1.0	24
45	Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. European Journal of Heart Failure, 2003, 5, 271-279.	2.9	24
46	Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. British Journal of Clinical Pharmacology, 2006, 62, 200-209.	1.1	24
47	Development of Sarcoidosis Following Completion of Treatment for Hepatitis C with Pegylated Interferon-Â2a and Ribavirin: A Case Report and Literature Review. Clinical Medicine and Research, 2010, 8, 163-167.	0.4	24
48	Functional status and co-morbidities are associated with in-hospital mortality among older patients with acute decompensated heart failure: a multicentre prospective cohort study. Age and Ageing, 2015, 44, 225-231.	0.7	24
49	Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 149-154.	1.0	23
50	Characteristics, outcome and treatments with cranial pachymeningitis. Medicine (United States), 2018, 97, e11413.	0.4	23
51	Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis: A Suitable Monitoring in Elderly Patients?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 134-136.	0.5	22
52	Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers. Molecular Pharmaceutics, 2016, 13, 766-773.	2.3	22
53	Efficacy of a New Oral Lubricant Solution in the Management of Psychotropic Drug-Induced Xerostomia. Journal of Clinical Psychopharmacology, 2007, 27, 437-443.	0.7	21
54	Improving Practices in US Hospitals to Prevent Venous Thromboembolism: Lessons from ENDORSE. American Journal of Medicine, 2010, 123, 1099-1106.e8.	0.6	21

#	Article	lF	Citations
55	The effect of morbid obesity on morphine glucuronidation. Pharmacological Research, 2017, 118, 64-70.	3.1	21
56	Protection against aspirin-induced gastric lesions by lansoprazole: Simultaneous evaluation of functional and morphologic responses. Clinical Pharmacology and Therapeutics, 1992, 52, 413-416.	2.3	19
57	Comparative Evaluation of Adherence to Antiretroviral Therapy in Subâ€Saharan African Native HIVâ€Infected Patients in France and Africa. Clinical Infectious Diseases, 2006, 43, 654-657.	2.9	19
58	Interaction between Aspirin and ACE Inhibitors in Patients with Heart Failure. Drug Safety, 2001, 24, 167-182.	1.4	18
59	Aspirin for the Prevention of Cardiovascular Events in the Elderly. Drugs and Aging, 2003, 20, 999-1010.	1.3	18
60	Enhanced Saquinavir Exposure in Human Immunodeficiency Virus Type 1-Infected Patients with Diarrhea and/or Wasting Syndrome. Antimicrobial Agents and Chemotherapy, 2004, 48, 538-545.	1.4	18
61	Plea for multitargeted interventions for severe COVID-19. Lancet Infectious Diseases, The, 2020, 20, 1122-1123.	4.6	18
62	Untreated highly viraemic pregnant women from Asia or subâ€6aharan Africa often transmit hepatitis B virus despite serovaccination to newborns. Liver International, 2015, 35, 409-416.	1.9	17
63	Agreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practices. Journal of General Internal Medicine, 2004, 19, 849-855.	1.3	15
64	Does Paracetamol Potentiate the Effects of Oral Anticoagulants?. Drug Safety, 2004, 27, 325-333.	1.4	15
65	Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. European Journal of Heart Failure, 2007, 9, 197-201.	2.9	15
66	Intravenous immunoglobulin efficacy for primary Sj $\tilde{A}$ ¶gren's Syndrome associated small fiber neuropathy. Autoimmunity Reviews, 2019, 18, 102387.	2.5	15
67	Value of a new rapid non-radioactive sequencing method for analysis of the cytomegalovirus UL97 gene in ganciclovir-resistant strains. Journal of Virological Methods, 1995, 51, 241-251.	1.0	14
68	Gastroduodenal tolerability of medium dose entericâ€coated aspirin: a placebo controlled endoscopic study of a new entericâ€coated formulation versus regular formulation in healthy volunteers. Fundamental and Clinical Pharmacology, 2000, 14, 155-157.	1.0	14
69	Antidepressant Agents in Short Bowel Syndrome. Clinical Therapeutics, 2014, 36, 2029-2033.e3.	1.1	14
70	Supplemental parenteral nutrition in critically ill patients. Lancet, The, 2013, 381, 1716.	6.3	13
71	Off-label Prescriptions: how to Identify Them, Frame Them, Announce Them and Monitor Them in Practice?. Therapie, 2013, 68, 233-239.	0.6	13
72	Long-term mortality in older patients discharged after acute decompensated heart failure: a prospective cohort study. BMC Geriatrics, 2017, 17, 34.	1.1	13

#	Article	IF	Citations
73	Prospective interventional study of tenofovir in pregnancy to prevent vertical transmission of hepatitis B in highly viremic women. European Journal of Gastroenterology and Hepatology, 2017, 29, 259-263.	0.8	13
74	Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome-a population pharmacokinetic study. British Journal of Clinical Pharmacology, 2001, 51, 557-565.	1.1	12
75	Pharmacodynamics of a New Ophthalmic Mydriatic Insert in Healthy Volunteers: Potential Alternative as Drug Delivery System Prior to Cataract Surgery*. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 547-554.	1.2	12
76	Absorption and Efficacy of Acetylsalicylic Acid in Patients With Short Bowel Syndrome. Annals of Pharmacotherapy, 2014, 48, 705-710.	0.9	12
77	Methadone and edema: a case-report and literature review. European Journal of Clinical Pharmacology, 2004, 59, 923-924.	0.8	11
78	Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake. Clinical Pharmacology and Therapeutics, 1995, 57, 461-470.	2.3	10
79	Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. Thrombosis Research, 2003, 111, 19-27.	0.8	10
80	How can a joint European health technology assessment provide an â€~additional benefit' over the current standard of national assessments?. Health Economics Review, 2022, 12, .	0.8	10
81	Comparative effect of aspirin and clopidogrel on arterial function in CHF. International Journal of Cardiology, 2006, 106, 61-66.	0.8	9
82	Novel melatonin-based treatments for major depression. Lancet, The, 2012, 379, 216.	6.3	9
83	Efficacy of Early Clinical Evaluation in Predicting Direct Home Discharge of Elderly Patients After Hospitalization in Internal Medicine. Southern Medical Journal, 2012, 105, 63-67.	0.3	9
84	Oral Ganciclovir Systemic Exposure Is Enhanced in HIV-Infected Patients With Diarrhea and Weight Loss. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 344-351.	0.9	8
85	Acceptability and feasibility of HIV testing in general medicine by ELISA or rapid test from finger-stick whole blood. Presse Medicale, 2018, 47, e15-e23.	0.8	8
86	Prophylaxis of Anaphylactoid Reaction to Antituberculous Drugs. Annals of Pharmacotherapy, 1997, 31, 373-374.	0.9	7
87	Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers. British Journal of Clinical Pharmacology, 2005, 59, 220-226.	1.1	7
88	Fatal Interruption of a 3TC-containing Regimen in a HIV-infected Patient Due to Re-activation of Chronic Hepatitis B Virus Infection. Scandinavian Journal of Infectious Diseases, 2004, 36, 533-535.	1.5	6
89	Optimizing the Use of Intravenous Therapy in Internal Medicine. American Journal of Medicine, 2013, 126, 925.e1-925.e9.	0.6	6
90	Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé―(CSIS) to be implemented (modalities, regulations, funding). Therapie, 2019, 74, 103-117.	0.6	6

#	Article	lF	Citations
91	Listeria monocytogenes Meningitis Following Imatinib Mesylate-Induced Monocytopenia in a Patient with Chronic Myeloid Leukemia. Clinical Infectious Diseases, 2005, 41, 1684-1685.	2.9	5
92	Effects of the addition of high-dose vitamin C to polyethylene glycol solution for colonic cleansing: A pilot study in healthy volunteers. Current Therapeutic Research, 2005, 66, 486-500.	0.5	5
93	Electrocardiographic Abnormalities in Centenarians and Octogenarians: A Caseâ€Matched Study. Annals of Noninvasive Electrocardiology, 2012, 17, 372-377.	0.5	5
94	Monoclonal <scp>B</scp> â€ell lymphocyte proliferation in a patient presenting with historical <scp>W</scp> hipple disease. Internal Medicine Journal, 2013, 43, 338-341.	0.5	4
95	Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010. Liver International, 2014, 34, 1349-1357.	1.9	4
96	Angina Caused by Calcific Constrictive Pericarditis. Annals of Internal Medicine, 2002, 137, 1012.	2.0	4
97	Persistent gastric-protective effect of antacid evaluated by measurement of transmucosal gastric potential difference. Clinical Pharmacology and Therapeutics, 1988, 44, 546-549.	2.3	3
98	Endoscopic evaluation of the gastrotolerance of short-term antalgic treatment with low dose k-diclofenac: a comparison of ibuprofen and aspirin. Fundamental and Clinical Pharmacology, 2001, 15, 61-63.	1.0	3
99	The [14C-N-methyl]-erythromycin breath test dosimetry complies with the French regulations for radiation safety. Fundamental and Clinical Pharmacology, 2003, 17, 349-353.	1.0	3
100	Clinical Experience. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, 1339-1342.	1.7	3
101	Roflumilast for chronic obstructive pulmonary disease. Lancet, The, 2005, 366, 1845.	6.3	3
102	Short article. European Journal of Gastroenterology and Hepatology, 2016, 28, 328-332.	0.8	3
103	How to measure the net benefit of treatment?. Therapie, 2017, 72, 51-61.	0.6	3
104	Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration. Therapie, 2018, 73, 185-191.	0.6	3
105	Effect of a Red Blood Cell Transfusion on Biological Markers Used to Determine the Cause of Anemia: A Prospective Study. American Journal of Medicine, 2018, 131, 319-322.	0.6	3
106	Maladies orphelines : évaluation et enregistrement des nouvelles thérapeutiques. Medecine/Sciences, 2005, 21, 69-72.	0.0	2
107	Is Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Before Starting Sulfa Useful In HIV-Infected Male Patients Originating From Sub-Saharan Africa?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e60-e63.	0.9	2
108	Long term treatment of atrial fibrillation in elderly patients: A decision analysis. International Journal of Cardiology, 2012, 155, 102-109.	0.8	2

#	Article	IF	Citations
109	Biosimilars: from Technical to Pharmacoeconomic Considerations. Therapie, 2015, 70, 47-55.	0.6	2
110	Protocolisation, utilisation et développement des médicaments anticancéreux dans le cadre de la mise en place de la T2A. Therapie, 2006, 61, 305-308.	0.6	1
111	Can Serum Soluble CD23 OR CD30 Predict the Occurence of Lymphoma in HIV-Infected Patients?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e58-e61.	0.9	1
112	Inadequate Therapeutic Response to a Recommended Antituberculosis Fixed-Dose Combination Regimen in an Overweight Patient with <i>Mycobacterium bovis</i> Infection. Annals of Pharmacotherapy, 2013, 47, e4-e4.	0.9	1
113	Hepatitis B virus (HBV) status of children born to HIV/HBV co-infected women in a French hospital: a cross-sectional study. Journal of the International AIDS Society, 2014, 17, 19632.	1.2	1
114	Hypothermia, a serious adverse effect of piribedil: The first human case report. Movement Disorders, 2017, 32, 942-943.	2.2	1
115	Venous Thromboembolism Prophylaxis Practices in Acutely III Medical Patients with Heart Failure (NYHA Class III or IV): Findings from IMPROVE Blood, 2005, 106, 1869-1869.	0.6	1
116	A case of Campylobacter fetus endocarditis of the tricuspid valve unaccompanied by fever. American Journal of Medicine, 2001, 111, 418.	0.6	O
117	Protocolisation, Use and Development of Anti-Cancer Drugs in the Context of T2A (Case-Mix Based) Tj ETQq1 1	0.784314	rgBT /Overloc
118	Good Medical Practice for Drugs. Definition, Guidelines, References, Field of Action and Applications. Therapie, 2008, 63, 275-280.	0.6	O
119	Moxifloxacin versus ethambutol in initial tuberculosis treatment. Lancet, The, 2009, 373, 2198.	6.3	O
120	Hepatic cytolysis and Hepatitis E Virus infection in HIV-positive patients. Retrovirology, 2010, 7, .	0.9	0
121	Vertical Transmission of Hepatitis B Virus. Annals of Internal Medicine, 2014, 161, 762.	2.0	O
122	Contribution of an Early Internal Medicine Rotation to the Clinical Reasoning Learning for Young Residents. Journal of Medicine and Life, 2020, 13, 183-186.	0.4	0
123	Peginterferon $\hat{l}$ ±-2a alone or with lamivudine increased response rates more than lamivudine alone for HBeAg-positive chronic hepatitis B. ACP Journal Club, 2006, 144, 5.	0.1	O
124	The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment. ACP Journal Club, 2006, 144, 4.	0.1	0
125	The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment. ACP Journal Club, 2006, 144, 4.	0.1	O
126	Peginterferon alpha-2a alone or with lamivudine increased response rates more than lamivudine alone for HBeAg-positive chronic hepatitis B. ACP Journal Club, 2006, 144, 5.	0.1	0